Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomized controlled trial

Background Because treatment with third-generation cephalosporins is associated with slow clinical improvement and high relapse burden for enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fever clearance and low relapse burden, we postulated that gatifloxacin would b...

詳細記述

保存先:

書誌詳細
主要な著者:	Arjyal, Amit, Basnyat, Buddha, Nhan, Ho Thi, Koirala, Samir, Giri, Abhishek, Joshi, Niva, Shakya, Mila, Pathak, Kamal Raj, Mahat, Saruna Pathak, Prajapati, Shanti Pradhan, Adhikari, Nabin, Thapa, Rajkumar, Merson, Laura, Gajurel, Damodar, Lamsal, Kamal, Lamsal, Dinesh, Yadav, Bharat Kumar, Shah, Ganesh, Shrestha, Poojan, Dongol, Sabina, Karkey, Abhilasha, Thompson, Corinne N, Thieu, Nga Tran Vu, Thanh, Duy Pham, Baker, Stephen, Thwaites, Guy E, Wolbers, Marcel, Dolecek, Christiane
フォーマット:	Technical Report
言語:	en_US
出版事項:	Lancet Infect Dis 2016 2016
主題:	Gatifloxacin versus Enteric Fever Nepal
オンライン･アクセス:	http://103.69.126.140:8080/handle/123456789/818
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

このレコードへの初めてのコメントを付けませんか!

Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomized controlled trial

類似資料